RxDoctor Payments Data

Eugene Kubitz, DPM

Podiatrist · Sandusky, OHNPI 1356387740

Payments from drug & device makers

$3,755in general payments, 2019–2025

Across 69 payments — averaging $54.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CDC Medical LLC$2K
  • Organogenesis Inc.$478
  • Stryker$380
  • Integra Lifesciences Corporation$353
  • Smith+Nephew$336
  • Mimedx Group, Inc.$148
  • plus $498 from 15 others

What the payments were for

  • Food & beverage$2,23960%
  • Education$1,51640%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,755 in reported general payments places this provider in the 75th percentile of 397 podiatrist providers in Ohio.

See all podiatrist providers in Ohio

Medicare billing

Part B allowed, 2024
$125,014
Medicare patients
327
Services billed
1,929

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.11$8,845
Nystatin88$1,638
CiclopiroxCiclopirox Olamine65$1,387
Terbinafine Hcl31$718
Gabapentin87$607
NyamycNystatin17$499
KlayestaNystatin20$414
Clobetasol Propionate15$414
Doxycycline Hyclate30$270
Betamethasone Valerate11$254
NystopNystatin12$191
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav11$147
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen21$65
Amoxicillin11$25

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$336$8,84511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 397 podiatrist providers in Ohio.

Other podiatrist in Sandusky

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →